Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.
J Rheumatol 2026; doi: 10.3899/jrheum.2025-0808In the originally published online version of this article, reference 8 was missing from the list of references.
APA
Fitzpatrick R, Demehri S, et al. (2026). Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.. The Journal of rheumatology. https://doi.org/10.3899/jrheum.2025-0808.C1
MLA
Fitzpatrick R, et al.. "Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.." The Journal of rheumatology, 2026.
PMID
41985925
Abstract
J Rheumatol 2026; doi: 10.3899/jrheum.2025-0808In the originally published online version of this article, reference 8 was missing from the list of references. The missing reference has now been added: "8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40."This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.